Trial Profile

Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 07 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amubarvimab/romlusevimab-Brii-Biosciences (Primary) ; Bamlanivimab (Primary) ; Camostat mesilate (Primary) ; Cilgavimab/tixagevimab (Primary) ; Cilgavimab/tixagevimab (Primary) ; Interferon beta-1a (Primary) ; Ogalvibart+C144-LS (Primary) ; SAB-185 (Primary) ; Casirivimab/imdevimab
Indications COVID 2019 infections; Post acute COVID 19 syndrome
Focus Adverse reactions; Therapeutic Use
Acronyms ACTIV-2; Adapt Out COVID

Most Recent Events

01 Jun 2025 Results published in the Contemporary Clinical Trials.
20 Jun 2024 According to a SAB Biotherapeutics media release, company name changed from SAB Biotherapeutics to SAB BIO.
06 Mar 2024 Results presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com